Difference between revisions of "Fruquintinib (Elunate)"
Jump to navigation
Jump to search
m |
|||
| Line 2: | Line 2: | ||
VEGFR inhibitor | VEGFR inhibitor | ||
| − | == | + | ==Diseases for which it is used== |
| − | + | *[[Colorectal cancer]] | |
==History of changes in NMPA indication== | ==History of changes in NMPA indication== | ||
Revision as of 00:26, 4 November 2023
Mechanism of action
VEGFR inhibitor
Diseases for which it is used
History of changes in NMPA indication
- 2018-09: Approved for the treatment of patients with metastatic colorectal cancer (“CRC”) who have been previously treated with fluoropyrimidine, oxaliplatin and irinotecan, including those who have previously received anti-VEGF therapy and/or anti-epidermal growth factor receptor (EGFR) therapy (RAS wild type). (Based on FRESCO)
Also known as
- Code name: HMPL-013
- Brand name: Elunate